NCT00527020View on ClinicalTrials.gov

First Time in Human Study With GSK1018921

PHASE1CompletedINTERVENTIONAL
Enrollment

27

Participants

Timeline

Start Date

August 10, 2007

Primary Completion Date

July 12, 2008

Study Completion Date

July 12, 2008

Conditions
Schizophrenia
Interventions
DRUG

GSK1018921

GSK1018921 will be supplied as 0.5, 5, 10 and 40 milligrams coated tablets.

DRUG

Nicotine Lozenges

Nicotine Lozenges will be supplied as 4 milligrams lozenges.

DRUG

Placebo

Placebo tablets will be given to the subjects.

Trial Locations (1)

14050

GSK Investigational Site, Berlin

Sponsors

Lead Sponsor

GlaxoSmithKline
All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY